专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO03065971A9 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS 审中-公开
标题翻译：用TYRPHOSTINS进行非骨髓瘤的全身性TOLOGENIC治疗
公开(公告)号：WO03065971A9
公开(公告)日：2003-11-20
申请号：PCT/IL0200467
申请日：2002-06-16
申请人： YISSUM RES DEV CO , HADASIT MED RES SERVICE , SLAVIN SHIMON , LEVITZKI ALEXANDER , GAZIT AVIV , MORECKI SHOSHANA
发明人： SLAVIN SHIMON , LEVITZKI ALEXANDER , GAZIT AVIV , MORECKI SHOSHANA
IPC分类号： A01K67/027 , A61K31/245 , A61K31/277 , A61K31/341 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/423 , A61K31/428 , A61K31/498 , A61K31/50 , A61K31/517 , A61K31/519 , A61K35/14 , A61K35/28 , A61K39/00 , A61K39/39 , A61K41/00 , A61K49/00 , A61L27/00 , A61P17/00 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , A61K
CPC分类号： A61K49/0004 , A61K31/277 , A61K31/404 , A61K31/50 , A61K31/517 , A61K31/519 , A61K39/00 , A61K39/001 , A61K39/39 , A61K41/00 , A61K2039/55511 , A61K2300/00
摘要： A method of inducing immune tolerance in a first mammal to antigens of a second, non-syngeneic, mammal, is disclosed. The method is utilized to minimize graft rejection and/or reduce graft-versus-host diseases in transplantation procedures and to produce hematopoietic mixed chimeras. Methods of determining the activity of tyrphostins and the optimal concentration thereof in this method are also disclosed.
摘要翻译：公开了在第一哺乳动物中诱导第二种非同基因哺乳动物的抗原的免疫耐受性的方法。该方法用于在移植过程中使移植物排斥最小化和/或减少移植物抗宿主疾病并产生造血混合嵌合体。还公开了测定该方法中酪氨酸磷酸化酶活性及其最佳浓度的方法。

12. 发明申请

WO2003065971A2 NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS 审中-公开
标题翻译：具有类型性的非骨髓性多发性骨髓瘤治疗
公开(公告)号：WO2003065971A2
公开(公告)日：2003-08-14
申请号：PCT/IL2002/000467
申请日：2002-06-16
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , SLAVIN, Shimon , MORECKI, Shoshana , LEVITZKI, Alexander , GAZIT, Aviv
发明人： SLAVIN, Shimon , MORECKI, Shoshana , LEVITZKI, Alexander , GAZIT, Aviv
IPC分类号： A61K
CPC分类号： A61K49/0004 , A61K31/277 , A61K31/404 , A61K31/50 , A61K31/517 , A61K31/519 , A61K39/00 , A61K39/001 , A61K39/39 , A61K41/00 , A61K2039/55511 , A61K2300/00
摘要： A method of inducing immune tolerance in a first mammal to antigens of a second, non-syngeneic, mammal, is disclosed. The method is utilized to minimize graft rejection and/or reduce graft-versus-host diseases in transplantation procedures and to produce hematopoietic mixed chimeras. Methods of determining the activity of tyrphostins and the optimal concentration thereof in this method are also disclosed.
摘要翻译：公开了一种在第一种哺乳动物中诱导免疫耐受的方法，该方法是第二种非同系哺乳动物的抗原。该方法用于在移植过程中最小化移植物排斥和/或减少移植物抗宿主病，并产生造血混合嵌合体。还公开了确定酪氨酸磷酸酶活性的方法及其在该方法中的最佳浓度。

13. 发明申请

WO1991016892A1 STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE 审中-公开
标题翻译：抑制EGF受体蛋白酪氨酸激酶的STYRYL化合物
公开(公告)号：WO1991016892A1
公开(公告)日：1991-11-14
申请号：PCT/US1991002931
申请日：1991-04-29
申请人： RORER INTERNATIONAL (HOLDINGS), INC. , LEVITZKI, Alexander , GILON, Chaim , CHOREV, Michael , GAZIT, Aviv
发明人： RORER INTERNATIONAL (HOLDINGS), INC.
IPC分类号： A61K31/415
CPC分类号： A61K31/275
摘要： A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.
摘要翻译：一种抑制患有这种病症的患者的细胞增殖的方法，包括向所述患者施用有效量的组合物，其包含与药学上可接受的载体，化合物或其药学上可接受的盐的混合物，其为取代的苯乙烯化合物，其为也可以是萘，茚满或苯并恶嗪; 包括腈和氰腈化合物，以及药学组合物，其与药学上可接受的载体的混合物包含药学上有效量的这种化合物。

14. 发明申请

WO2008149345A3 TRI-ARYL COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME 审中-公开
标题翻译：三芳基化合物及其组合物
公开(公告)号：WO2008149345A3
公开(公告)日：2010-02-25
申请号：PCT/IL2008000747
申请日：2008-06-03
申请人： UNIV BEN GURION , PRIEL ESTHER , GAZIT AVIV , SLAVIN SHIMON , YITZCHAK SARA
发明人： PRIEL ESTHER , GAZIT AVIV , SLAVIN SHIMON , YITZCHAK SARA
IPC分类号： A01N33/02 , A61K31/13 , C12P19/34
CPC分类号： C07C215/80 , A61K31/03 , A61K31/05 , A61K31/055 , A61K31/136 , A61K31/66 , A61K31/695 , C07C39/367 , C07C43/225 , C07C43/23 , C07C215/50 , C07D213/16 , C07D213/30 , C07D295/096 , C07D295/135 , C07F9/5022
摘要： The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.
摘要翻译：本发明涉及一类新的三芳基化合物，其组合物及其制备方法。

15. 发明申请

WO2006087718A1 EXTENSION OF LIFESPAN WITH DRUGS 审中-公开
标题翻译：延长寿命与药物
公开(公告)号：WO2006087718A1
公开(公告)日：2006-08-24
申请号：PCT/IL2006/000205
申请日：2006-02-16
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , SLAVIN, Shimon , GAZIT, Aviv
发明人： SLAVIN, Shimon , GAZIT, Aviv
IPC分类号： A61K31/277 , C07C255/40 , C07C255/41 , C07C255/42 , C07C317/46 , C07C327/44 , A61P43/00
CPC分类号： C07C255/40 , C07C255/37 , C07C317/46 , C07C323/60 , C07C327/44
摘要： New compounds, inhibiting protein tyrosine kinases (PTKs) or steroid-related enzymes (SREs), which affect apoptosis in malignant tissues, and can be used in the preparation of medicaments for treating various disorders, and for elongating the lifespan of a subject while sustaining that subject in good health. Further, a method and antiaging compositions are provided for extending the lifespan.
摘要翻译：新化合物，抑制蛋白酪氨酸激酶（PTK）或类固醇相关酶（SREs），其影响恶性组织中的细胞凋亡，并且可用于制备用于治疗各种疾病的药物并延长受试者的寿命，同时维持那个问题身体健康。此外，提供了延长使用寿命的方法和抗衰老组合物。

16. 发明申请

WO9928304A3 PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION AND COMPOSITIONS 审中-公开
标题翻译： PDGF受体激酶抑制化合物，它们的制备和组合物
公开(公告)号：WO9928304A3
公开(公告)日：1999-08-12
申请号：PCT/US9825320
申请日：1998-11-30
申请人： YISSUM RES DEV CO , FRIEDMAN MARK M , LEVITZKI ALEXANDER , GAZIT AVIV , BANAI SHMUEL , GERTZ DAVID S , GOLOMB GERSHON
发明人： LEVITZKI ALEXANDER , GAZIT AVIV , BANAI SHMUEL , GERTZ DAVID S , GOLOMB GERSHON
IPC分类号： C07D215/20 , A61K31/275 , A61K31/403 , A61K31/404 , A61K31/4155 , A61K31/47 , A61K31/498 , A61K31/4985 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/08 , C07D209/18 , C07D241/38 , C07D241/42 , C07D403/06 , C07D409/04 , C07D487/04 , C07F17/02 , C07D241/36 , A01N43/58 , C07D471/00
CPC分类号： C07D409/04 , C07D241/42 , C07D487/04
摘要： PDGF receptor kinase inhibitory compounds of the quinoxaline family, methods for their synthesis and containment in slow release pharmaceutical preparations, and their use for treatment of proliferative malignant and non-malignant diseases or disorders by local or systemic application. A compound according to the invention includes a tyrphostin of general formula (I), wherein R1 and R2 are each independently selected from the group consisting of alkyl, alkoxy, halogen, nitro and amine and Ar is selected from the group consisting of phenyl, ferrocene, thiophene, furane, pyrrole, indole, thiazole, imidazole and pyridine.
摘要翻译：喹喔啉家族的PDGF受体激酶抑制化合物，它们在缓释药物制剂中的合成和包含的方法，以及它们用于通过局部或全身应用来治疗增殖性恶性和非恶性疾病或病症的用途。根据本发明的化合物包括通式（I）的tyrphostin，其中R 1和R 2各自独立地选自烷基，烷氧基，卤素，硝基和胺，且Ar选自苯基，二茂铁，噻吩，呋喃，吡咯，吲哚，噻唑，咪唑和吡啶。

17. 发明申请

WO1995014464A1 SSI TYRPHOSTINS AND PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译： SSI TYRPHOSTINS和药物组合物
公开(公告)号：WO1995014464A1
公开(公告)日：1995-06-01
申请号：PCT/US1994013535
申请日：1994-11-23
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KUPOT-HOLIM HEALTH INSURANCE INSTITUTE OF THE GENERAL FEDERATION OF LABOUR IN ERETZ-ISRAEL , LEVITZKI, Alexander , NOVOGRODSKY, Abraham , GAZIT, Aviv
发明人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , KUPOT-HOLIM HEALTH INSURANCE INSTITUTE OF THE GENERAL FEDERATION OF LABOUR IN ERETZ-ISRAEL
IPC分类号： A61K31/165
CPC分类号： A61K31/275
摘要： SSI thyrphostins are useful in preventing LPS induced toxicity, TNF alpha induced toxicity, LPS induced increases in TNF alpha levels, nitric oxide production, and the treatment of septic shock and various immune disorders. Featured are novel compounds and pharmaceutical compositions, both of which may be used in the methods of prevention and/or treatment described herein, as well as methods for making the novel compounds.
摘要翻译： SSI thyrphostins可用于预防LPS诱导的毒性，TNFα诱导的毒性，LPS诱导的TNFα水平升高，一氧化氮产生以及脓毒性休克和各种免疫疾病的治疗。特征是新颖的化合物和药物组合物，它们都可用于本文所述的预防和/或治疗方法，以及制备新化合物的方法。

18. 发明申请

WO1991016305A1 HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE 审中-公开
标题翻译：抑制EGF受体酪氨酸激酶的杂环化合物
公开(公告)号：WO1991016305A1
公开(公告)日：1991-10-31
申请号：PCT/US1991002597
申请日：1991-04-16
申请人： RORER INTERNATIONAL (HOLDINGS), INC. , SPADA, Alfred, P. , PERSONS, Paul, E. , LEVITZKI, Alexander , GILON, Chaim , GAZIT, Aviv
发明人： RORER INTERNATIONAL (HOLDINGS), INC.
IPC分类号： C07D209/18
CPC分类号： C07D233/64 , C07D209/08 , C07D209/18 , C07D213/57 , C07D231/12 , C07D317/62
摘要： Heteroarylethenediyl or heteroarylethenediyl aryl compounds wherein the heteroaryl group can be mono- or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents, and pharmaceutical compositions comprising said compounds, and the use thereof for inhibiting cell proliferation in a patient suffering from such disorder.
摘要翻译：杂芳基二烯基或杂芳基二芳基芳基化合物，其中杂芳基可以是单或双环杂芳基，芳基可以是单环或双环杂芳基或双环或三环碳环，所述化合物任选被取代或多取代，条件是杂芳基不是呋喃基或噻吩基，当乙烯二基具有偕基的氰基取代基时，以及包含所述化合物的药物组合物及其用于抑制患有这种病症的患者的细胞增殖的用途。

19. 发明申请

WO2008149353A3 TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
标题翻译： TELOMERASE激活化合物及其使用方法
公开(公告)号：WO2008149353A3
公开(公告)日：2010-02-25
申请号：PCT/IL2008000756
申请日：2008-06-04
申请人： UNIV BEN GURION , GAZIT AVIV , SLAVIN SHIMON , PRIEL ESTHER , YITZCHAK SARA
发明人： GAZIT AVIV , SLAVIN SHIMON , PRIEL ESTHER , YITZCHAK SARA
IPC分类号： A01N43/04
CPC分类号： C07C215/80 , A61K31/03 , A61K31/05 , A61K31/055 , A61K31/136 , A61K31/66 , A61K31/695 , C07C39/367 , C07C43/225 , C07C43/23 , C07C215/50 , C07D213/16 , C07D213/30 , C07D295/096 , C07D295/135 , C07F9/5022
摘要： The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.
摘要翻译：本发明涉及一系列化合物和包含其的组合物用于活化端粒酶和治疗与之相关的疾病，病症和/或病症的用途。

20. 发明申请

WO2004013091A2 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES 审中-公开
标题翻译： 4-ANILIDO取代喹啉腈及其作为抗生殖因子受体激动剂的抑制剂
公开(公告)号：WO2004013091A2
公开(公告)日：2004-02-12
申请号：PCT/IL2003/000632
申请日：2003-07-31
申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM , GAZIT, Aviv , LEVITZKI, Alexander
发明人： GAZIT, Aviv , LEVITZKI, Alexander
IPC分类号： C07D
CPC分类号： C07D401/12 , A61K31/517 , C07D239/86 , C07D239/88 , C07D239/94 , C07D239/95 , C07D403/04 , C07D403/12 , C07D417/12 , C07D417/14
摘要： The present invention provides 4-anilido substituted quinazoline compounds which are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity, and pharmaceutical compositions comprising these compounds. The present invention further provides methods of inhibiting the activity of a protein tyrosine kinase (PTK), for example an EGFR kinase, comprising the step of contacting the PTK with an effective inhibitory amount of any of the quinazoline compounds defined herein. The present invention further provides a method of inhibiting the activity of a protein tyrosine kinase (PTK) in a subject, for example an EGFR kinase, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The present invention further provides a method of treating or preventing a protein tyrosine kinase (PTK) related disorder in a subject, for example an EGFR related disorder, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The quinazoline compounds are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.
摘要翻译：本发明提供了作为蛋白酪氨酸（PTK）激酶活性，特别是表皮生长因子受体（EGFR）激酶活性的有效抑制剂的4-苯胺基取代的喹唑啉化合物，以及包含这些化合物的药物组合物。本发明进一步提供了抑制蛋白酪氨酸激酶（PTK），例如EGFR激酶的活性的方法，其包括使PTK与有效抑制量的本文定义的任何喹唑啉化合物接触的步骤。本发明进一步提供了抑制受试者例如EGFR激酶中蛋白质酪氨酸激酶（PTK）的活性的方法，包括向受试者施用治疗有效量的本文定义的任何喹唑啉化合物的步骤。本发明还提供了治疗或预防受试者中的蛋白酪氨酸激酶（PTK）相关病症的方法，例如EGFR相关病症，其包括向受试者施用治疗有效量的任何定义的喹唑啉化合物于此。喹唑啉化合物可用于治疗各种PTK相关疾病，例如细胞增殖性疾病，纤维化病症，代谢紊乱和癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式